44 results
8-K
EX-99.1
ALGS
Aligos Therapeutics, Inc.
6 Aug 24
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
4:05pm
regulatory feedback from the FDA supporting subsequent studies of chronic suppressive therapy with sustained HBV DNA suppression as the primary … and showed consistent, potent antiviral activity across multiple cohorts of untreated chronic hepatitis B (CHB) patientsData from ≤ 72 weeks following an oral
8-K
EX-99.1
ALGS
Aligos Therapeutics, Inc.
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
across multiple cohorts of untreated chronic hepatitis B (CHB) patients receiving once daily doses of ALG-000184 as monotherapy or in combination
8-K
EX-99.1
ig3pmp
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
SC TO-I
EX-99
g2govwfk
30 Jan 24
Issuer tender offer statement
7:04am
424B3
5vgpm fmk
28 Nov 23
Prospectus supplement
4:01pm
8-K
EX-99.1
0mk424qcx057m5 w5iq
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
7unbrr9
3 Aug 23
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
wsnvr
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
CORRESP
9rb0v8onyf
22 Dec 22
Correspondence with SEC
12:00am
8-K
EX-99.1
ecrd zgka8n
2 Nov 22
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
23rfiwdq
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm